AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer’s disease (AD) cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with